1Jones C. NMR assays for carbohydrate-based vaccines. J Pharm Biomed Anal, 2005, 38 (5): 840-850.
2Abeygunawardana C, Williams TC, Sumner JS, et al. Development and validation of an NMR-based identity assay for bacterial polysaceharides. Anal Biochem, 2000, 279 (2): 226-240.
3Stowell CP, Lee VC. Neoglycoproteins: the preparation and application of synthetic glycoproteins. Adv Carbohydr Chem Biochem, 1980, 37 (2): 225-281.
6Szu SC, Stone AL, Robbins JD, et al. Vi capsular polysaccharideprotein conjugates for prevention of typoid fever.Preparation,characterization,and immunogenicity in laboratory animals. J Exp Med, 1987, 166(5): 1510-1524.
7Shafer DE, Toll B, Schuman RF, et al. Activation of soluble polysaccharides with 1-cyano-4-dimethyl-aminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents.Ⅱ. Selective crosslinking of proteins to CDAP-activated polysaccharides. Vaccine, 2000, 18(13): 1273-1281.
8Lees A, Sen G, LopezAcosta A. Versatile and efficient synthesis of protein-polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry. Vaccine, 2006, 24(6): 716-729.
9Wen E, Cinelli LD, Murray D, Lander R J, et al. Purification of a polysaccharide conjugate vaccine using microfihration membranes in backpulsing mode. J Memsci, 2005, 258( 2-2): 23-34.
10Shafer DE, Sehuman RF, Lees A. Rapid and complete adsorption of unconjugated protein from protein-polysaccharide conjugate vaccines. Vaccine, 2001, 19( 11-12): 1547-1558.
二级参考文献16
1Reinert P. The role of pneumococcal and haemophilus type B vaccination in the prevention of acute otitis media. Clinical Microbiologic Infection,1997,3:59-61.
3Jacobs, Michael R. Prevention of otitis media: Role of pneumococcal conjugate vaccine in reducing incidence and antibiotic resistance. The Journal of Pediatrics,2002, 141:287-293.
4Selman S, Hayes D, Perin LA, et al. Pneumococcal conjugate vaccine for young children. Management Care, 2000,9: 49-52.
5Karma P. Vaccination and otitis media. ORL J Otorhinolaryngol Relat Spec, 2002,64: 80-85.
6CJ, Wang TR, Frasch CE. Immunogenicity in mice of pneumococcal glycoconjugate vaccines using pneumococcal protein carriers. Vaccine,2001,19:3216-3225.
7Lee HJ,Kang JH,Henrichsen J,et al.Immunogenicity and safety of a 23-valent pneumococcal polysaccharide Vaccine in healthy children and in children at increased risk of pneumococcal infection.Vaccine,1995,13(16):1533-1538.
8Bulter JC,Breiman RF,Lipman HB,et al.Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States,1978-1994:implications for development of a conjugate vaccine J Infect Dis,1995,171:885-889.
9Hausdorff WP,Bryant J,Paradiso PR,et al.The contribution of specific pneumococcal serogroups to different disease manifestations:Immplications for conjugate vaccine formulation and use.Part II.Clin Infect Dis,2000,30:122-140.
10Vidarson G,Sigurdardottir ST,Gudnason T,et al.Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine.Infect Immun,1998,66(6):2866-2870.
10Kimmel SR. Using the tetravalent meningoeoccal polysaccharide- protein conjugate vaccine in the prevention of meningoeoecal dis- ease [J]. Ther Clin Risk Manag, 2008, 4 (4): 739-745.
